CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 236 target
Drug / intervention
mFOLFIRINOX-FOLFIRI intensified chemotherapy +1 moredrug
Likely dose
mFOLFIRINOX-FOLFIRI intensified chemotherapy 85mg/m2from record
Key inclusion· 9
  • Age 19-75 years
  • Adenocarcinoma of colon confirmed by histology
  • Stage II-III colon cancer (AJCC 8th edition; Stage II must be high-risk with multiple recurrence factors)
  • Completed 6 cycles of FOLFOX or 4 cycles of CAPOX adjuvant chemotherapy after R0 resection
Key exclusion· 18
  • Pregnant or lactating women
  • Positive pregnancy test at baseline (postmenopausal status requires ≥12 months amenorrhea)
  • Reproductive-age patients unwilling to use contraception during and 6 months (female) or 3 months (male) after treatment
  • Clinically significant cardiac disease: unstable angina, symptomatic CAD, CHF, NYHA >II arrhythmia, or ACS/MI within 6 months

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05534087
NCT05534087Phase 3RecruitingOn TrackUpdated 19mo ago
Long Recruiting

A Randomized Controlled Phase III Trial of Treatment Intensification in Stage II-III Colon Cancer Patients With Positive MRD During Adjuvant Chemotherapy

Seoul National University Hospital·interventional·Posted Sep 9, 2022·Updated Nov 29, 2024

In Brief

A Phase 3 clinical trial evaluating mFOLFIRINOX-FOLFIRI intensified chemotherapy and FOLFOX or CAPOX adjuvant chemotherapy for Colon Cancer. Currently recruiting, targeting 236 participants across 3 sites.

Detailed Summary

This study is a prospective, open-label, randomized phase 3 clinical trial. It aims to investigate if the early introduction of intensified chemotherapy (3 months of modified FOLFIRINOX) improves the 3-year disease-free survival rate compared to standard treatment (FOLFOX/CAPOX for an additional three months to complete six months of standard adjuvant chemotherapy) in patients with stage 2-3 colon cancer in whom ctDNA MRD in the part 1 study remained positive during adjuvant FOLFOX/CAPOX chemotherapy

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColon Cancer
CountriesSouth Korea
Collaborators--

Timeline

Phase 3Recruiting
20232024202520262027202820292030
First PostedSep 9, 2022
Enrollment StartDec 15, 2022
Primary CompletionSep 30, 2028
Study CompletionSep 30, 2030
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 3.8 years agoPrimary completion in 2.2 years

Interventions

mFOLFIRINOX-FOLFIRI intensified chemotherapydrug

(1) Modified FOLFIRINOX (mFOLFIRINOX) regimen: 6 cycles every 2 weeks * Oxaliplatin 85mg/m2 IV infusion over 120 min D1 * Leucovorin 400mg/m2 IV (concurrently with oxaliplatin) * Irinotecan 150mg/m2 IV infusion over 60-90 min D1 * 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2

FOLFOX or CAPOX adjuvant chemotherapydrug

1. FOLFOX regimen: 6 cycles every 2 weeks * Oxaliplatin 85mg/m2 IV infusion over 120 min D1 * Leucovorin 400mg/m2 IV infusion over 120 min (concurrently with oxaliplatin) * 5-fluorouracil 400mg/m2 IV bolus D1 * 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2 or 2. CAPOX regimen: 4 cycles every 3 weeks * Oxaliplatin 130mg/m2 IV infusion over 120 min D1 * Capecitabine 1,000mg/m2 PO bid D1-14